- Source : Press Release
- Date : 2021-05-31
- Companies : Merck KGaA
Personnel Changes at Merck Group Level to Further Push Science & Technology Based Strategic Growth Trajectory
Darmstadt, Germany, May 31, 2021 – Merck is further pushing its science and technology based strategic growth trajectory with two appointments to key senior leadership positions on Group level. In both cases internal candidates will be promoted which underlines the high quality of Merck’s top talent pipeline.
Effective June 1, Roman Werth will become new Head of Group Strategy, M&A and M Ventures, reporting to Belén Garijo, Chair of the Executive Board and CEO of Merck. Isabel de Paoli, currently heading Group Strategy and Transformation, has decided to leave the company to turn to other career opportunities outside of Merck.
“I would like to warmly thank Isabel de Paoli for her contributions to Merck’s strategic development. In particular, the development of our global Innovation Hubs in China, Israel, the U.S. and Darmstadt is closely associated with her name. I wish Isabel de Paoli all the very best and much success in her future endeavors,” said Garijo.
In addition to Strategy Development and M&A on Group level, Roman Werth will be in charge of M Ventures, Merck’s €400 million corporate venture capital fund headquartered in Amsterdam, with offices in the U.S. and Israel. M Ventures is mandated to invest into transformational technologies with the potential to significantly impact Merck’s core business areas. Until now, Werth has been heading the M&A department at Merck. Before joining the company in 2008, he worked at Siemens and Continental. He holds an MBA from Dresden Technical University.
“Roman Werth is an outstanding expert and strategic forward thinker. His combined leadership of Group Strategy, M&A and M Ventures will ensure integrated strategy development and execution, paving the way to drive Merck’s organic and inorganic growth agenda more effectively,” said Garijo.
To emphasize the central importance of science and technology as key drivers of Merck’s growth ambition, the new position of a Chief Science and Technology Officer will be created. Laura Matz will take over that position effective July 1, reporting to Belén Garijo. Her areas of responsibility will include Digital, Enterprise Data, Future Insight as well as Merck’s global Innovation hubs in China, Israel, the U.S. and at Darmstadt headquarters.
Laura Matz joined Merck in 2019 through the Versum Materials acquisition, and has since then served as Head of Planarization in the Semiconductor Materials business while also leading a business sector wide digital program for quality innovation with customers in Electronics. Matz had been with Versum Materials since 2016 and had previously worked at Air Products and Texas Instruments. She has a PhD in Analytical Chemistry from Washington State University.
“Laura Matz manages to envision the future of science and technology and at the same time she has the pioneering spirit to bring this vision into reality. She will, in particular, pay close attention to cross-sectoral innovation creation to fully leverage Merck’s unique advantages in serving the needs of patients, scientists and customers worldwide,” said Garijo.
All Merck news release are distributed by email at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Electronics.